pharma · Atopic Dermatitis · COVID-19
Qilu Pharmaceuticals
Qilu Pharmaceutical (Hainan) Co.,
Qilu Pharmaceutical (Hainan) is a pharma organization headquartered in CN. Primary therapeutic focus areas include Atopic Dermatitis, COVID-19. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent
CN HQ
1958 Founded
243 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Founded
- 1958
- Employees
- 243
- Programs
- 2
- Drugs
- 4
- Patents
- 0
QLS1128 A-Dose 1~5 and Ritonavir
Phase 1 · small molecule · COVID-19
QLS1128 A-Dose 1~5 and Ritonavir for COVID-19 is a Phase 1 program (small_molecule) at Qilu Pharmaceutical (Hainan) Co., with 1 ClinicalTrials.gov record(s).
Internal code QLS1128-101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Qilu Pharmaceutical (Hainan) Co.,
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- COVID-19
- Status
- active
- Trials
- 1